title: Efficacy of ossein-hydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis.
abstract: OBJECTIVE
  There is increasing evidence to suggest that ossein-hydroxyapatite complex (OHC) is more effective than calcium supplements in maintaining bone mass. The aim of this meta-analysis was to determine whether OHC has a different clinical effect on bone mineral density (BMD) compared with calcium carbonate (CC).
  
  
  METHODS
  A meta-analysis of randomized controlled clinical trials was carried out to evaluate the efficacy of OHC versus CC on trabecular BMD. We identified publications on clinical trials by a search of electronic databases, including MEDLINE (1966-November 2008), EMBASE (1974-November 2008), and the Cochrane Controlled Clinical Trials Register.The primary endpoint was percent change in BMD from baseline. Data were pooled in a random-effects model, and the weighted mean difference was calculated. A sensitivity analysis that excluded trials without full data was performed.
  
  
  RESULTS
  Of the 18 controlled trials initially identified, 6 were included in the meta-analysis. There was no significant heterogeneity among the included trials. The percent change in BMD significantly favored the OHC group (1.02% [95% CI, 0.63-1.41], P < 0.00001). These results were confirmed in the sensitivity analysis.
  
  
  CONCLUSIONS
  OHC is significantly more effective in preventing bone loss than CC.
authors.affiliation: Obstetrics and Gynaecology Unit, Hospital Clínic i Provincial, Barcelona, Spain.
authors.forename: Camil
authors.initials: C
authors.lastname: Castelo-Branco
authors.forename: Manel
authors.initials: M
authors.lastname: Ciria-Recasens
authors.forename: María J
authors.initials: MJ
authors.lastname: Cancelo-Hidalgo
authors.forename: Santiago
authors.initials: S
authors.lastname: Palacios
authors.forename: Javier
authors.initials: J
authors.lastname: Haya-Palazuelos
authors.forename: Jordi
authors.initials: J
authors.lastname: Carbonell-Abelló
authors.forename: Josep
authors.initials: J
authors.lastname: Blanch-Rubió
authors.forename: María J
authors.initials: MJ
authors.lastname: Martínez-Zapata
authors.forename: José
authors.initials: J
authors.lastname: Manasanch
authors.forename: Lluís
authors.initials: L
authors.lastname: Pérez-Edo
mesh_terms: D000284:Administration, Oral; D015519:Bone Density / Q000187:drug effects*; D001851:Bone Diseases, Metabolic / Q000517:prevention & control*; D001862:Bone Resorption / Q000517:prevention & control*; D002119:Calcium Carbonate / Q000494:pharmacology / Q000627:therapeutic use*; D017886:Durapatite / Q000494:pharmacology / Q000627:therapeutic use*; D055317:Evidence-Based Practice; D006801:Humans; D010024:Osteoporosis / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D017886:Durapatite; D002119:Calcium Carbonate